Act locally. Think globally.

AlbyPharma Ireland, is a well-established pharmaceutical company with 40 plus years of experience supplying European and US markets.

First oral FDA-Approved Beta-Lactam facility in Europe.

Has solid dosage forms, liquid-line, sachets & dry powder suspension manufacturing capabilities.

Full in-house R&D capabilities.

Fully equipped Analytical & Development labs.

Scroll down

Europe’s only independent FDA Approved Beta-Lactam plant.

Both plants (Unit I & Unit II) are self contained facilities, capable of supporting the entire production process completely. Stability and validation testing are conducted on site.
The process technology includes but not limited to: Pelletizing and Coating, Sustained Release Tablets and Hard Gelatin/Soft Gelatin Capsules.

Quality is our pride & commitment

Working with AlbyPharma will give you access to a very high standard of analytical services and capabilities. As a partner you have a purpose and AlbyPharma team will make sure that the means will follow.


Our SAP system is fully operating and backed-up in cloud, which means that all data will be fully secured at all time and this gives our customers a trust in our process.

It is effectively provides real-time business applications and link to number of other systems to track shipments and delivery as ongoing live stream.

Go to top

Quality is our pride & commitment

Go to article: Home | The Scottish Uprising Go to article: In this issueGo to article: NSFGo to article: ContentsGo to article: Daiichi JitsugyoGo to article: NewsGo to article: Hapa Company InsightGo to article: BioadviceGo to article: The pharma industry briefingGo to article: Komtur Pharmaceuticals Company InsightGo to article: Komtur PharmaceuticalsGo to article: Where is the UK’s supply of Migraleve?Go to article: AtoZ-CRO GmbH Company InsightGo to article: AtoZ-CRO GmbHGo to article: Drugs from corn? Harvesting Mirexus’ phytoglycogen nano-particleGo to article: Phoenix Group Company InsightGo to article: Phoenix Group Go to article: Castleman disease: does machine learning hold the key to better treatment?Go to article: Capsugel Company InsightGo to article: CalleryGo to article: A health check for Scotland’s pharmaceutical industry Go to article: ImmuMap Company Insight Go to article: ImmuMapGo to article: Moderna’s gamble: what’s behind biotech’s biggest-ever IPO?Go to article: Centaur Clinical | Company InsightGo to article: Centaur ClinicalGo to article: DelSiTech: leveraging silica’s properties to improve drug deliveryGo to article: Alpex Pharma Go to article: AlbypharmaGo to article: ‘Gene genie’: can CRISPR/Cas9 deliver on its promise to transform genome therapy?Go to article: ZenatekGo to article: EventsGo to article: SanofiGo to article: Event: CPhl JapanGo to article: PfanstiehlGo to article: Next issue